J&J cuts R&D at Netherlands infectious disease, vaccine unit
J&J cuts R&D at Netherlands infectious disease, vaccine unit
J&J cuts R&D at Netherlands infectious disease, vaccine unit
Published: Aug 24, 2023
By Tristan Manalac
BioSpace
Johnson & Johnson appears to be winding down research at its infectious disease and vaccine unit, save for a few select programs, according to Fierce Biotech on Wednesday, citing sources familiar with the matter.
A Janssen spokesperson said J&J is “planning to exit other R&D programs in ID&V,” though the unit will continue to supply its HIV vaccine and work on a preventive vaccine for E. coli, reported Fierce, adding that the company’s other infectious disease assets—such as those for dengue and tuberculosis—will be moved under Janssen’s global health portfolio.
Earlier on Wednesday, Dutch news outlet De Telegraaf also reported that J&J was planning to end its vaccine R&D work at the company’s facility in Leiden. Though the company has yet to confirm how many jobs will be affected, the Netherlands-based campus employs some 2,500 people, a quarter of whom belong to the section focused on vaccines and infectious diseases, according to Reuters.
J&J was part of the COVID-19 boom with its single-shot vaccine winning the FDA’s emergency authorization in February 2021. However, in May 2022, citing the associated risk of the potentially life-threatening thrombosis with thrombocytopenia syndrome, the regulator limited the vaccine to adults who are ineligible to receive other COVID-19 shots, or to those who specifically prefer J&J’s vaccine and would otherwise not get immunized.
A year later, in May 2023, the CDC announced that J&J’s COVID-19 vaccine was no longer available in the U.S.
Beyond COVID-19, J&J has also been steadily shifting away from its infectious disease programs in recent months. In March 2023, the company indicated that it was dropping out of the respiratory syncytial virus vaccine race and was discontinuing its Phase III EVERGREEN trial.
According to a J&J spokesperson at the time, this decision came after a review of the competitive landscape and is part of a sweeping review of Janssen’s pipeline and research focus.
During its second-quarter earnings report in July 2023, J&J confirmed that it was slimming down its infectious disease business and was eliminating seven programs, most of which were in hepatitis B. Assets in HIV, influenza and hepatitis D were also axed. Instead, the company will narrow its focus to only a couple of its most promising assets in HIV, Ebola, COVID-19 and E. coli leading to urinary tract infections and neonatal meningitis.
Tristan Manalac is an independent science writer based in Metro Manila, Philippines. He can be reached at [email protected] or [email protected].
Source: BioSpace
This site uses cookies. By continuing to browse the site, you are agreeing to our use of cookies.
Accept settingsHide notification onlySettingsWe may request cookies to be set on your device. We use cookies to let us know when you visit our websites, how you interact with us, to enrich your user experience, and to customize your relationship with our website.
Click on the different category headings to find out more. You can also change some of your preferences. Note that blocking some types of cookies may impact your experience on our websites and the services we are able to offer.
These cookies are strictly necessary to provide you with services available through our website and to use some of its features.
Because these cookies are strictly necessary to deliver the website, refusing them will have impact how our site functions. You always can block or delete cookies by changing your browser settings and force blocking all cookies on this website. But this will always prompt you to accept/refuse cookies when revisiting our site.
We fully respect if you want to refuse cookies but to avoid asking you again and again kindly allow us to store a cookie for that. You are free to opt out any time or opt in for other cookies to get a better experience. If you refuse cookies we will remove all set cookies in our domain.
We provide you with a list of stored cookies on your computer in our domain so you can check what we stored. Due to security reasons we are not able to show or modify cookies from other domains. You can check these in your browser security settings.
We also use different external services like Google Webfonts, Google Maps, and external Video providers. Since these providers may collect personal data like your IP address we allow you to block them here. Please be aware that this might heavily reduce the functionality and appearance of our site. Changes will take effect once you reload the page.
Google Webfont Settings:
Google Map Settings:
Google reCaptcha Settings:
Vimeo and Youtube video embeds: